Skip to main content
. 2023 Feb 7;83(8):1203–1213. doi: 10.1158/0008-5472.CAN-22-2236

Figure 4.

Figure 4. Global CpG island hypermethylation in PCBM is associated with the PRC2 complex. A, Mean methylation of CpG sites in relation to CpG islands in normal prostate, primary, and metastatic samples. P values computed from Wilcoxon tests. B, Mean methylation of CpG sites in relation to CpG islands in normal prostate, primary, and metastatic samples, stratified by TMPRSS2-ERG fusion, SPOP mutation, or neither. P values computed from Wilcoxon tests. C, Gene set enrichment analysis on DM CpG sites between primary tumors and normal prostates, metastases and normal prostates, and metastases and primary tumors, using curated gene sets from MSigDB. Pathways shown are from the union of the top 10 DM pathways from each of the three comparisons. D, Same as C but showing the union of the 10 most DM pathways between SPOP-mutant or TMPRSS2-ERG fusion metastases against metastases with neither alteration. E, Expression of EZH2 in primary tumors and metastases from targeted RNA-seq. P values computed from Wilcoxon tests. F, Same as E, with samples stratified by TMPRSS2-ERG fusion, SPOP mutation, or neither.

Global CpG island hypermethylation in PCBM is associated with the PRC2 complex. A, Mean methylation of CpG sites in relation to CpG islands in normal prostate, primary, and metastatic samples. P values computed from Wilcoxon tests. B, Mean methylation of CpG sites in relation to CpG islands in normal prostate, primary, and metastatic samples, stratified by TMPRSS2-ERG fusion, SPOP mutation, or neither. P values computed from Wilcoxon tests. C, Gene set enrichment analysis on DM CpG sites between primary tumors and normal prostates, metastases and normal prostates, and metastases and primary tumors, using curated gene sets from MSigDB. Pathways shown are from the union of the top 10 DM pathways from each of the three comparisons. D, Same as C but showing the union of the 10 most DM pathways between SPOP-mutant or TMPRSS2-ERG fusion metastases against metastases with neither alteration. E, Expression of EZH2 in primary tumors and metastases from targeted RNA-seq. P values computed from Wilcoxon tests. F, Same as E, with samples stratified by TMPRSS2-ERG fusion, SPOP mutation, or neither.